iShares Global Healthcare

Johnson & Johnson Expected to Grow Sales 7% in 2026, Seen as Strong Investment Due to Stable Model and Dividend History

Zacks Raises UnitedHealth's Q1 2027 EPS Estimate to $6.87

Eli Lilly & UNICEF Launch US$50m Partnership Program for Childhood Chronic Diseases

WHO confirms Merck's Ervebo vaccine as candidate for Ebola prevention

Multiple Institutional Investors Disclose Increased Stakes in UnitedHealth Group on May 19, 2026

Lilly Asia Ventures Participates in Accro Bioscience's $50 Million Series C Financing

Investment firm Gambit Capital Management makes a new $26.54 million investment in Eli Lilly

Wells Fargo Raises UnitedHealth Group's Price Target to $397

Japan Approves Eli Lilly's Zepbound for Obstructive Sleep Apnea

Eli Lilly Scales Up AI-Driven Drug R&D and Production with Dell Solutions

Merck Plans to Issue $6 Billion in Bonds to Fund Terns Pharmaceutical Acquisition

Judge grants Luigi Mangione's request to suppress evidence in UnitedHealth CEO murder case

UnitedHealth Group will hold its Annual General Meeting on June 2, 2026

Harbour BioMed releases positive preclinical obesity data on its potential rival drug, LET003

Merck Announces Experimental Endometrial Cancer Drug Meets Primary Endpoint in Late-Stage Trial

Novo Nordisk plans to launch Wegovy oral weight-loss drug outside the US, intensifying competition with Eli Lilly

Eli Lilly announces its RET kinase inhibitor selpercatinib has entered a Phase III clinical trial for the first-line treatment of RET fusion-positive lung cancer

Berkshire Hathaway exited its entire position in UnitedHealth Group during the first quarter, causing the stock to slide 4% overnight.

AstraZeneca and Daiichi Sankyo's Enhertu Approved by FDA for HER2+ Early Breast Cancer

AstraZeneca's Baxfendy Approved in US, Outpacing Mineralys Therapeutics

Amesite

InMed Pharmaceuticals

Meiwu Tech

Co-Diagnostics

Phoenix Asia

Generation Income Properties

MetaVia

BAYVIEW ACQUISITION CORPORATION COM USD0.0001 (S/R) 17/11/2028

Virax Biolabs

Rubico

Pinned News

置顶新闻

ProShare Advisors LLC Buys 623,752 Shares of Gilead Sciences, Inc. $GILD

The latest batch of 13F filings has been released: In Q1, Berkshire Hathaway increased its stake in Google Class A shares by over 200%, propelling it to the position of its seventh-largest holding. The firm completely exited positions held for nearly seven years—including Amazon, as well as Visa, Mastercard, and UnitedHealth—while simultaneously making a return to the airline sector after a six-year hiatus, investing $2.65 billion to establish a new position in Delta Air Lines. Bridgewater Associates, meanwhile, initiated new positions in TSMC and the Gold ETF (GLD) for the first time; it also increased its holdings in Amazon (elevating it to its top holding), Nvidia, Broadcom, and Micron. Conversely, the firm liquidated its stakes in Salesforce and ServiceNow, and trimmed its positions in Mastercard, Adobe, and others. Institutional capital is currently converging on AI computing power and safe-haven assets. How many of the stocks in your portfolio have caught the eye of these investment giants?

The latest batch of 13F filings has been released: In Q1, Berkshire Hathaway increased its stake in Google Class A shares by over 200%, propelling it to the position of its seventh-largest holding. The firm completely exited positions held for nearly seven years—including Amazon, as well as Visa, Mastercard, and UnitedHealth—while simultaneously making a return to the airline sector after a six-year hiatus, investing $2.65 billion to establish a new position in Delta Air Lines. Bridgewater Associates, meanwhile, initiated new positions in TSMC and the Gold ETF (GLD) for the first time; it also increased its holdings in Amazon (elevating it to its top holding), Nvidia, Broadcom, and Micron. Conversely, the firm liquidated its stakes in Salesforce and ServiceNow, and trimmed its positions in Mastercard, Adobe, and others. Institutional capital is currently converging on AI computing power and safe-haven assets. How many of the stocks in your portfolio have caught the eye of these investment giants?

Big funds' 13Fs are out: betting on AI compute and safe havens

GILD

ARKG

LABU

SBIO

IBBQ

ProShare Advisors LLC increased its stake in Gilead Sciences, Inc. by 39.1% in Q4, acquiring 623,752 shares, bringing its total to 2,217,290 shares valued at $272.15 million. Other institutional investors also adjusted their holdings. Gilead's stock opened at $129.67, with a market cap of $160.99 billion. The company reported $2.03 EPS, exceeding estimates, and announced a quarterly dividend of $0.82 per share.

Market Beat

Gilead Sciences

Gilead Sciences, Inc.

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

VG Health

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

iShares Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

Health Care Select Sector SPDR

VanEck Biotech ETF

iShares US Pharma

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

JPMorgan Chase & Co. has lowered its price target for HCA Healthcare from $535.00 to $490.00, maintaining a 'neutral' rating. The stock currently has a consensus rating of 'Moderate Buy' with an average target price of $515.77. HCA's stock traded down to $405.77, with a market cap of $90.02 billion. Analysts forecast an EPS of 30.07 for the current fiscal year.

HCA Healthcare

iShares US Healthcare Providers

SPDR S&P Health

JPMorgan Chase

Goldman Sachs

KeyCorp

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

GS Hldg R

KEYCORP DEP SHS REP 1/40TH NON CUM PER PFD SER G

KEYCORP DEP SHS REPSTG 1/40TH INT PERP NON CUM H

KEYCORP DEP SHS REP 1/40TH PERP PFD SER F USD25

KEYCORP DEP SHS REP 1/40TH NON CUM PFD SER E

HCA Healthcare (NYSE:HCA) Price Target Cut to $490.00 by Analysts at JPMorgan Chase & Co.

ABBV

AbbVie and CVS Health appear expensive with trailing P/E multiples over 40, but non-recurring expenses inflate these figures. AbbVie’s forward P/E is 15, while CVS Health’s is 13, indicating they may be undervalued. AbbVie faced a significant drop in net income due to a $2.7 billion charge, while CVS reported a $4 billion loss from goodwill impairment. Both companies show potential for better performance, making them attractive investment options despite their current valuations.

nasdaq

CVS Health

Abbvie

NVIDIA

Intel

S&P 500

NVIDIA Corporation

2 Stocks That Are Much Cheaper Than They Look

DoctorDerm has announced a comprehensive rebrand and the expansion of its telehealth dermatology platform, introducing new prescription treatments. The rebrand emphasizes simplicity and personalized care, moving away from one-size-fits-all solutions. New offerings include the Copper Peptide Skin Complex for skin quality and the Lash Growth Serum for enhancing lash appearance. Both treatments are available nationwide after evaluation by licensed providers, reflecting DoctorDerm's commitment to accessible, clinically guided skincare.

MorningStar

DoctorDerm Unveils Rebrand and Expands Platform with New Prescription Skin and Lash Treatments

REGN

Yesterday, Regeneron Pharma's stock price plummeted 9.82% to $629.68, with a large bearish candlestick engulfing the gains of the previous days. The 5-day and 10-day moving averages were decisively breached, severely damaging the short-term bullish arrangement. The MACD daily line issued a bearish signal below the zero axis, indicating that selling pressure has shifted from testing to active attack, with the short-term trend rapidly weakening. The trading volume reached $1.87 billion, far exceeding the recent average level, showing clear signs of panic selling, with bears completely in control

Technical Forecast

Regeneron Pharma

Pre-market trend | Regeneron Pharma (REGN) plummeted nearly 10% on May 18, is short interest accelerating?

RNXT

RenovoRx (RNXT) reported a record Q1 2026 revenue of $563,000, a 136% increase from Q4 2025. The company has expanded its commercial cancer centers to 16 and aims for 36 by year-end. Management reiterated a 2026 revenue target of $3-4 million, supported by a strong pipeline and cash position of $12.4 million. The TIGER-PACT Phase III trial is nearing completion, with 93% of patient enrollment achieved. Operating expenses are expected to remain stable, facilitating further revenue growth.

Motley Fool

RenovoRx

SPDR S&P Health Equip

iShares US Medical Devices

RenovoRx (RNXT) Q1 2026 Earnings Transcript

PHAR

Pharming has published a corporate presentation reaffirming its full-year revenue guidance of USD 405 million to USD 425 million, projecting 8% to 13% growth. Operating expenses are expected to be between USD 330 million and USD 335 million. First-quarter revenue fell 8%, with RUCONEST revenue down 15%, while Joenja revenue rose 34%. The company highlighted pipeline milestones for Joenja and leniolisib, with key readouts expected in H2 2026.

PUBT

Pharming Group NV

Pharming publishes corporate presentation outlining rare disease portfolio, 2026 outlook

RenovoRx will present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20, 2026. CEO Shaun Bagai and CFO Mark Voll will speak at 1:40 p.m. ET, moderated by Scott Henry from Alliance Global Partners.

RenovoRx CEO, CFO to speak at Alliance Global Partners annual healthcare showcase

VANI

Vivani Medical director Gregg Williams acquired 1,587,301 common shares for $1,999,999.26 at $1.26 per share. His indirect beneficial ownership increased to 34,531,785 shares, while direct holdings stand at 4,799,200 shares.

Vivani Medical

Vivani Medical director Gregg Williams acquires common shares worth $1,999,999.26

VTGN

VistaGen Therapeutics has appointed Angel S. Angelov as chief medical officer, effective May 18, 2026. Angelov previously served as chief medical officer at Theranica and held senior roles at Karuna Therapeutics, Neurocrine Biosciences, Novartis, and Teva.

NOVARTIS AG

Vistagen Therap

Neurocrine Biosciences

Teva Pharmaceutical Industries

Novartis AG

VistaGen appoints Angel Angelov as chief medical officer

Johnson & Johnson (NYSE: JNJ) is highlighted as a strong investment choice due to its robust business model, AAA credit rating, and a history of 64 consecutive dividend increases. Despite facing legal challenges and potential government price negotiations, the company is expected to grow sales by 7% year-over-year by 2026. Its diversified portfolio and essential products position it well to navigate economic downturns, making it a reliable option for investors seeking stability.

Johnson & Johnson

S&P Global

Meet the Dividend King With a Higher Credit Rating Than the U.S. Government

iShares Global Healthcare(IXJ.US)